|
Orthologous residues
|
|
PLCB3 (human): S1105‑p, PLCB3 (mouse): S1105‑p, PLCB3 (rat): S1105‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
2D analysis, [32P] bio-synthetic labeling, mutation of modification site, phosphoamino acid analysis, phosphopeptide mapping
|
|
Relevant cell lines - cell types - tissues:
COS (fibroblast), HeLa (cervical), PHM1-49 (myometrial)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human, monkey
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
PKCA (human)
|
pharmacological activator of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
phorbol ester
|
|
|
|
increase
|
|
|
